Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cara Haymaker

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2024
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Nature|March 18, 2021
Identification of bacteria-derived HLA-bound peptides in melanomaShelly Kalaora, Adi Nagler, Deborah Nejman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical OutcomeMarie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2024
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Nature|March 18, 2021
Identification of bacteria-derived HLA-bound peptides in melanomaShelly Kalaora, Adi Nagler, Deborah Nejman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical OutcomeMarie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 11